Value-Based Cardiology

ARTICLES

Dennis P. Scanlon, PhD; Zachary T. Bloomgarden, MD, MACE; Robert Gabbay, MD, PhD, FACP; Michael Gardner, MD; and John A. Johnson, MD, MBA, discuss the relevance of scientific evidence from clinical trials in the treatment decision-making process, the value of postmonitoring patients, and the significance and use of quality measures in helping to deliver data that can improve care for patients with diabetes who are at risk for cardiovascular events.
Zachary T. Bloomgarden, MD, MACE, remarks on controversies in clinical practice due to changes in lipid guidelines published by the American Heart Association and the American College of Cardiology.
Two studies presented at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure held in Florence, Italy, hold good news for patients with heart failure who get flu shots.
Dennis P. Scanlon, PhD; Zachary T. Bloomgarden, MD, MACE; Robert Gabbay, MD, PhD, FACP; Michael Gardner, MD; and John A. Johnson, MD, MBA, discuss the results of recent clinical trials that evaluated cardiovascular outcomes associated with various diabetes treatments when used as add-on therapy.
A secondary analysis of data from the TECOS trial of sitagliptin finds that the drug does not affect the risk for heart failure hospitalization or related adverse clinical outcomes in people with type 2 diabetes

EVENTS

July 25-27, 2015
Vancouver, BC, Canada
August 14-16, 2015
Mackinac Island,MI
Compendia
Diabetes Compendium
Oncology Compendium
Reimbursement Compendium
Know Your News
HF Compendium
$AD300x250BB$
$vacMongoViewPlus$